Evaluating the Role of IL-6-174 G/C (rs1800795) Gene Polymorphism in Modulating Serum Levels of Some Inflammatory Biomarker and Therapeutic Outcomes with Rituximab in Iraqi Rheumatoid Arthritis Patients
DOI:
https://doi.org/10.31351/vol35iss3pp89-96Keywords:
Genetic Polymorphism, IL-6, Response, Rheumatoid Arthritis, RituximabAbstract
Rituximab is a chimeric monoclonal antibody used in the treatment of rheumatoid arthritis (RA). However, patients receiving it show various degrees of responsiveness without knowing the exact causes behind this diversity. Interleukin-6, among other inflammatory biomarkers, is involved in RA pathogenicity. This study investigated the role of IL-6-174 G/C (rs1800795) gene polymorphism at the promoter region and its possible effect on serum level of different inflammatory biomarkers and response to Rituximab (RTX) among RA patients, and whether this genotyping can aid clinicians in choosing eligible patients for RTX. Ninety adult RA patients from the Rheumatology Unit of Baghdad Teaching Hospital were recruited for this cross-sectional study. All were receiving RTX intravenously. Blood samples were taken from them for genetic analysis and measuring serum levels of IL-1 beta, IL-6, TNF-, and their effect on Rituximab response, which was measured using disease activity score in 28 joints (DAS 28 score). From the pooled sample of 90 patients, 50 of them were RTX responders, and 40 of them were RTX non-responders. Regarding the studied SNP, no significant difference was obtained between the expected and observed proportion of rs1800795 C>G (P-value=0.378). The proportion of patients with G allele was significantly higher in the RTX responders (73%) compared to RTX non-responders (45%) (P-value<0.001). IL-6 level was significantly higher in the CC phenotype (48.06 ±23.53) compared to the GC phenotype (36.97 ±19.57) and GG phenotype (26.48 ±18) (P-value=<0.001). As conclusion for optimizing RTX treatment among RA patients, the genotyping study of the promoter region of IL-6 could be a valuable marker, different allelic at rs1800795 affected the serum levels of different inflammatory biomarkers and extended to affect RTX response showing that GG presence reflected a better response to RTX treatment than GC and CC genotypes.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Petrovská N, Prajzlerová K, Vencovský J, Šenolt L, Filková M. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmunity Reviews. 2021;20(5):102797.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):15
Ostrowska M, Maśliński W, Prochorec-Sobieszek M, Nieciecki M, Sudoł-Szopińska I. Cartilage and bone damage in rheumatoid arthritis. Reumatologia. 2018;56(2):111-120. doi: 10.5114/reum.2018.75523. Epub 2018 May 4. PMID: 29853727; PMCID: PMC5974634.
Karami J, Aslani S, Tahmasebi MN, Mousavi MJ, Sharafat 4Vaziri A, Jamshidi A, et al. Epigenetics in rheumatoid arthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of the disease. Immunology & Cell Biology. 2020;98(3):171-86.
Li J, Li L, Wang Y, Huang G, Li X, Xie Z, et al. Insights into the role of DNA methylation in immune cell development and autoimmune disease. Front Cell Dev Biol. 2021;9:747958.
Hussein RG, Al-Atrakji MQ. Impact of Infliximab Biosimilar (Ixifi®) Trough Levels on Disease Activity and Inflammatory Markers in Iraqi Rheumatoid Arthritis Patients. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2024;7(1 (Special)):36-40.
Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.
Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Frontiers in immunology. 2022;13:1024068.
Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl_5):v3-v11.
Hussein HM, Kasim AA. Correlation between Serum Levels of Factor I, CD59, Interferon-gamma, and Interleukin-6 with the Response to Rituximab in Iraqi Patients with Rheumatoid Arthritis. Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219). 2024;7(1 (Special)):41-6
Yogita S, Neeraj K, Devyani T. Interleukin 6 in patients with rheumatoid arthritis. In: Payam B, editor. Interleukins. Rijeka: IntechOpen; 2021. Chapter 3.
Amr K, El-Awady R, Raslan H. Assessment of the− 174G/C (rs1800795) and− 572G/C (rs1800796) interleukin 6 gene polymorphisms in Egyptian patients with rheumatoid arthritis. Open access Macedonian journal of medical sciences. 2016;4(4):574.
Fabris M, Quartuccio L, Lombardi S, Benucci M, Manfredi M, Saracco M, et al. Study on the possible role of the −174G>C IL 6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo. 2010;62:253–8.
Hennessey V, Leon Novelo L, Li J, Zhu L, Chi E, Ibrahim J. A Bayesian Joint model for Longitudinal DAS28 Scores and Competing Risk Informative Drop Out in a Rheumatoid Arthritis Clinical Trial. 2018.
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35:745–57
Mohammed SI, Jamal MY, Alshamari IO. The association of genetic polymorphisms in tumor necrosis factor-alpha and interleukins with disease severity or response to biological therapy in Iraqi rheumatoid arthritis patients: A narrative review. Al-Rafidain Journal of Medical Sciences 2023;4:24-33.
Amr K, El-Awady R, Raslan H. Assessment of the -174G/C (rs1800795) and -572G/C (rs1800796) Interleukin 6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis. Open Access Maced J Med Sci. 2016;4(4):574-7.
Al-Awadhi AM, Haider MZ, Al-Awadi AM, Kalarikkal AK, Sukumaran J, Hasan EA, et al. Analysis of association between interleukin-6 (IL6), interleukin-13 (IL13) and tumor necrosis factor-alpha (TNF-α) gene polymorphisms and genetic susceptibility of rheumatoid arthritis in Kuwaiti Arab. Open J Rheumatol Autoimmune Dis. 2022;12(4):99–113.
Tischendorf J, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, et al. The interleukin‐6 (IL6)–174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. International journal of immunogenetics. 2007;34(6):413-8.
Iacopetta B, Grieu F, Joseph D. The− 174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. British journal of cancer. 2004;90(2):419-22.
Ulhaq ZS, Soraya GV, Budu, Wulandari LR. The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis. Scientific reports. 2020;10(1):17453.
Muzasti RA, Hariman H, Daulay ER. The Influence of− 174 G/C Interleukin 6 Promoter Gene Polymorphism to Interleukin 6 Concentration in the End Stage Renal Disease Patients with Dialysis: A Single-Center Experience in Indonesia. Open Access Macedonian Journal of Medical Sciences. 2020;8(A):563-6.
Iacopetta B, Grieu F, Joseph D. The− 174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. British journal of cancer. 2004;90(2):419-22.
Melo TS, Silva MLe, Silva MLdM, Duarte AP, Gueiros LA. Characterization of clinical, laboratory, IL-6 serum levels, and IL-6-174 G/C genetic polymorphisms in patients with rheumatoid arthritis and Sjögren’s syndrome. Revista da Associação Médica Brasileira. 2021;67(11):1600-4.27
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
